Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Despite the rapid adoption of immunotherapies in advanced non–small cell lung cancer (advNSCLC), knowledge gaps remain about their real‐world (rw) performance. Methods: This retrospective, observational, multicenter analysis used the Flatiron Health deidentified electronic health record‐derived database of rw patients with advNSCLC who received treatment with PD‐1 and/or PD‐L1 (PD‐[L]1) inhibitors before July 1, 2017 (N = 5257) and had ≥6 months of follow‐up. The authors investigated PD‐(L)1 line of treatment and PD‐L1 testing rates and the relationship between overall survival (OS) and rw intermediate endpoints: progression‐free survival (rwPFS), rw time to progression (rwTTP), rw time to next treatment (rwTTNT), and rw time to discontinuation (rwTTD). Results: First‐line PD‐(L)1 inhibitor use increased from 0% (in the third quarter of 2014 [Q3 2014]) to 42% (Q2 2017) over the study period. PD‐L1 testing also increased (from 3% in Q3 2015 to 70% in Q2 2017). The estimated median OS was 9.3 months (95% CI, 8.9‐9.8 months), and the estimated rwPFS was 3.2 months (95% CI, 3.1‐3.3 months). Longer OS and rwPFS were associated with ≥50% PD‐L1 percentage staining results. Correlations (⍴) between OS and intermediate endpoints were ⍴ = 0.75 (95% CI, 0.73‐0.76) for rwPFS and ⍴ = 0.60 (95% CI, 0.57‐0.63) for rwTTP, and, for treatment‐based intermediate endpoints, correlations were ⍴ = 0.60 (95% CI, 0.56‐0.64) for rwTTNT (N = 856) and ⍴ = 0.81 (95% CI, 0.80‐0.82) for rwTTD. Conclusions: The use of first‐line PD‐(L)1 inhibitors and PD‐L1 testing has substantially increased, with better outcomes for patients who have ≥50% PD‐L1 percentage staining. Intermediate rw tumor‐dynamics estimates were moderately correlated with OS in patients with advNSCLC who received immunotherapy, highlighting the need for optimizing and standardizing rw endpoints to enhance the understanding of patient outcomes outside clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 3×
“We consider the results of traditionally designed PD-(L)1 inhibitor clinical trials important reference points, although cohort differences prevent direct crossstudy comparisons (Table 3).(5,8-11,18) Typically, real-world patients fare worse than those in clinical trials; this may reflect the more heterogeneous charac…”
BackgroundNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 3×
“We consider the results of traditionally designed PD-(L)1 inhibitor clinical trials important reference points, although cohort differences prevent direct crossstudy comparisons (Table 3).(5,8-11,18) Typically, real-world patients fare worse than those in clinical trials; this may reflect the more heterogeneous charac…”
BackgroundHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 4×
“We consider the results of traditionally designed PD-(L)1 inhibitor clinical trials important reference points, although cohort differences prevent direct crossstudy comparisons (Table 3).(5,8-11,18) Typically, real-world patients fare worse than those in clinical trials; this may reflect the more heterogeneous charac…”
BackgroundInfluentialPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×
“PD-L1 expression testing and reporting practices also evolved: 1) testing rates before the initiation of PD-(L)1 inhibitor treatment increased; 2) the proportion of PD-L1 reports with a binary positive/negative result interpretation started decreasing in Q4 2016, and the concomitant increase in reports without a binar…”
Result
Cited by
Multimodal data fusion for cancer biomarker discovery with deep learning
Steyaert, S., Pizurica, M., Nagaraj, D., Khandelwal, P., Hernandez-Boussard, T., Gentles, A. J., & Gevaert, O. (2023) · Nature Machine Intelligence · doi:10.1038/s42256-023-00633-5 · Cited by 402
Ma, X., Long, L., Moon, S., Adamson, B. J. S., & Baxi, S. S. (2020) · medRxiv · doi:10.1101/2020.03.16.20037143 · Cited by 353
Evaluating eligibility criteria of oncology trials using real-world data and AI
Liu, R., Rizzo, S., Whipple, S., Pal, N., Pineda, A. L., Lu, M., Arnieri, B., Lu, Y., Capra, W., Copping, R., et al. (2021) · Nature · doi:10.1038/s41586-021-03430-5 · Cited by 322
Toward a More Precise Future for Oncology
Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48
Zhang, X., Xiao, Q., Zhang, C., Zhou, Q., & Xu, T. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18262 · Cited by 14
“7 Although surgical resection is currently the most efficient way to eradicate LC in clinical settings, it might not be appropriate for every patient.”
Background
Metadata
- Authors
- Khozin, S., Miksad, R. A., Adami, J., Boyd, M., Brown, N. R., Gossai, A., Kaganman, I., Kuk, D., Rockland, J. M., Pazdur, R., Torres, A. Z., Zhi, J., & Abernethy, A. P.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2019-08-05
- Volume
- 125
- Issue
- 22
- Pages
- 4019-4032
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2965486449
- Cited by
- 137
- References
- 6
- FWCI
- 7.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer. https://app.cochat.ai/papers/10.1002/cncr.32383
- The paper
- Khozin, S., Miksad, R. A., Adami, J., Boyd, M., Brown, N. R., Gossai, A., Kaganman, I., Kuk, D., Rockland, J. M., Pazdur, R., Torres, A. Z., Zhi, J., & Abernethy, A. P. (2019). Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer. Cancer. https://doi.org/10.1002/cncr.32383
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.